Praluent ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

praluent

pharmacy retailing (nz) ltd t/a healthcare logistics - alirocumab 75 mg/ml;   - solution for injection - 75 mg/ml - active: alirocumab 75 mg/ml   excipient: histidine polysorbate 20 sucrose water for injection - primary hypercholesterolaemia praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.